SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 196 filers reported holding SAGE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.84 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201 | -56.1% | 9,744 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $458 | +12.0% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $409 | +9.9% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $372 | -99.9% | 9,744 | 0.0% | 0.00% | -33.3% |
| Q3 2022 | $382,000 | +21.3% | 9,744 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $315,000 | -2.5% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $323,000 | -22.2% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $415,000 | -3.9% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $432,000 | -22.0% | 9,744 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $554,000 | -25.5% | 9,744 | -2.0% | 0.00% | -25.0% |
| Q1 2021 | $744,000 | -13.5% | 9,944 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $860,000 | +72.7% | 9,944 | +22.1% | 0.01% | +25.0% |
| Q3 2020 | $498,000 | -26.5% | 8,144 | -50.0% | 0.00% | +33.3% |
| Q2 2020 | $678,000 | -39.2% | 16,288 | +16.3% | 0.00% | -89.3% |
| Q2 2017 | $1,115,000 | -12.8% | 14,000 | -22.2% | 0.03% | -22.2% |
| Q1 2017 | $1,279,000 | – | 18,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |